Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 24, 2012
Reinfection redux
Andrew A Vernon, M Elsa Villarino
International Journal of Epidemiology
|
October 16, 2003
Commentary: Can capture-recapture analysis of epidemiological and molecular data help us understand recent tuberculosis transmission?
Andrew A Vernon, M Scott McNabb
American Journal of Respiratory and Critical Care Medicine
|
November 10, 2004
In the treatment of tuberculosis, you get what you pay for
Andrew A Vernon, Michael F Iademarco
Plos Medicine
|
September 7, 2019
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance
Christian Lienhardt, Andrew A Vernon, Marco Cavaleri, et al.
Frontiers in Public Health
|
February 25, 2025
Health inequities among persons with disabilities: a global scoping review
Emre Umucu, Andrew A Vernon, Deyu Pan, et al.
Plos Medicine
|
February 28, 2020
Advances in clinical trial design: Weaving tomorrow's TB treatments
Christian Lienhardt, Andrew Nunn, Richard Chaisson, et al.
Plos Medicine
|
August 22, 2008
Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens
William J Burman, Mark F Cotton, Diana M Gibb, et al.
American Journal of Preventive Medicine
|
June 19, 2018
Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis
Gibril J Njie, Sapna Bamrah Morris, Rachel Yelk Woodruff, et al.
American Journal of Respiratory and Critical Care Medicine
|
September 6, 2005
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis
Ian M Rosenthal, Kathy Williams, Sandeep Tyagi, et al.
American Journal of Respiratory and Critical Care Medicine
|
April 1, 2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis
Ian M Rosenthal, Kathy Williams, Sandeep Tyagi, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 24, 2012
Reinfection redux
Andrew A Vernon, M Elsa Villarino
International Journal of Epidemiology
|
October 16, 2003
Commentary: Can capture-recapture analysis of epidemiological and molecular data help us understand recent tuberculosis transmission?
Andrew A Vernon, M Scott McNabb
American Journal of Respiratory and Critical Care Medicine
|
November 10, 2004
In the treatment of tuberculosis, you get what you pay for
Andrew A Vernon, Michael F Iademarco
Plos Medicine
|
September 7, 2019
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance
Christian Lienhardt, Andrew A Vernon, Marco Cavaleri, et al.
Frontiers in Public Health
|
February 25, 2025
Health inequities among persons with disabilities: a global scoping review
Emre Umucu, Andrew A Vernon, Deyu Pan, et al.
Plos Medicine
|
February 28, 2020
Advances in clinical trial design: Weaving tomorrow's TB treatments
Christian Lienhardt, Andrew Nunn, Richard Chaisson, et al.
Plos Medicine
|
August 22, 2008
Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens
William J Burman, Mark F Cotton, Diana M Gibb, et al.
American Journal of Preventive Medicine
|
June 19, 2018
Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis
Gibril J Njie, Sapna Bamrah Morris, Rachel Yelk Woodruff, et al.
American Journal of Respiratory and Critical Care Medicine
|
September 6, 2005
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis
Ian M Rosenthal, Kathy Williams, Sandeep Tyagi, et al.
American Journal of Respiratory and Critical Care Medicine
|
April 1, 2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis
Ian M Rosenthal, Kathy Williams, Sandeep Tyagi, et al.
Page
of 2